# Elanco Animal Health Inc: Form 10-Q for the period ended Jun 30, 2023

- Company: [Elanco Animal Health Inc](/companies/elan.md) (CIK 1739104)
- Form: 10-Q
- Filed: 2023-08-07
- Accepted by EDGAR: Aug 7, 2023, 16:11 ET
- Period: 2023-06-30
- Accession: 0001739104-23-000013
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000013/elan-20230630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1739104/000173910423000013/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-04-01 to 2023-06-30 | $1.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2023-01-01 to 2023-06-30 | $2.31bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-04-01 to 2023-06-30 | $434.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2023-01-01 to 2023-06-30 | $928.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2023-04-01 to 2023-06-30 | $81.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2023-01-01 to 2023-06-30 | $162.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-04-01 to 2023-06-30 | $353.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2023-01-01 to 2023-06-30 | $680.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2023-04-01 to 2023-06-30 | $74.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-01-01 to 2023-06-30 | $138.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-04-01 to 2023-06-30 | $18.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2023-01-01 to 2023-06-30 | $23.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$97.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | $6.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 492,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 492,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$84.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2023-06-30 | $367.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $3.65bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $15.80bn | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $1.28bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $8.38bn | us-gaap:Liabilities |
| Long-term debt | at 2023-06-30 | $6.02bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-06-30 | $39.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2023-06-30 | $7.42bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 36,116 characters.

### Introduction

Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our 2022 Form 10-K, may cause our actual results, financial position and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.

### Business Overview

Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in the Pet Health and Farm Animal product categories.

We offer a diverse portfolio of approximately 200 brands that make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health in 2020, we expanded our presence in retail and e-commerce channels, allowing our customers to shop where and how they want.

### Key Trends and Factors Affecting Our Results of Operations

Acquisition and Integration Activity: As previously disclosed, in April 2023, we successfully completed the integration of the Bayer Animal Health business into Elanco's Enterprise Resource Planning (ERP) system. In connection with the integration, we communicated commercial shipping blackout periods that occurred in April, and, given this timing, we believe certain customers modified purchasing habits, which we estimate caused a shift of revenue from the second quarter of 2023 to the first quarter of approximately $90 million to $110 million. In addition, we extended payment terms related to approximately $35 million of revenue in the first quarter of 2023 in certain international markets, driven by the duration of the aforementioned blackout periods. While first quarter 2023 revenues benefited from this shift in purchases, this resulted in a corresponding decrease in revenues during the second quarter of 2023.

During the six months ended June 30, 2023, we continued to incur costs related to integration activities, including the build out of processes and systems to support our global organization. Integration costs totaled $75 million for the six months ended June 30, 2023. We anticipate some additional costs through 2023 as we finalize these integration activities.

Macroeconomic Factors: Our operations are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, supply chain disruption, higher interest rates and inflationary pressures. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions and has also led to volatility in consumer behavior, particularly impacting our over-the-counter (OTC) retail parasiticide products. We expect these global macroeconomic pressures to continue through 2023.

While there has been an overall improvement in the conditions related to the COVID-19 pandemic in 2023 as compared to 2022, we may continue to experience geographical variations. The extent to which the COVID-19 pandemic may continue to impact our financial condition and results of operations remains uncertain.

Russia-Ukraine Conflict: As a global animal health leader, we have an obligation to support the health of animals and people. At the center of that work is ensuring access and availability of food and avoiding the spread of disease. At this time, we are limiting our business in Russia to only the essential products that support these needs, while complying with all imposed sanctions. We do not currently manufacture products or source any materials from companies in Russia for use in our products, but to continue to support the health of animals and people, we may in the future source products in Russia because of new laws requiring products sold in Russia to be produced there as well. We do not conduct business with the Russian government. During the six months ended June 30, 2023, revenue to Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of June 30, 2023 represented less than 1% of our consolidated assets.

Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products *Seresto* and *Advantage Family*, respectively, typically occurs during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere. Therefore, total revenue for our pet health products through the first half of 2023 is not necessarily an indication of performance during the second half of the year.

### Product Development and Regulatory Update

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we develop internally and may develop with partners and products that we are able to obtain through licenses or acquisitions, and the life cycle management of our existing products. We believe we are an industry leader in animal health R&D, with a track record of successful product innovation, business development and commercialization. For example, in July 2023 we launched our canine parvovirus monoclonal antibody in the U.S., the first and only approved therapeutic solution to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract.

Seresto: On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the *Seresto* flea and tick collar and confirmed the continued registration of the collar. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA-registered pet products. Based on comprehensive data from the study, the EPA concluded that *Seresto* continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm. We believe the EPA's conclusions align with those of authorities worldwide, with *Seresto* being approved for use in more than 80 counties and supported by veterinary professionals around the globe. The robust scientific evidence continues to support *Seresto's* safe use.

### Results of Operations

The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.

### Revision of Prior Period Financial Statements Primarily Relating to Tax Valuation Allowance Adjustment

In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. As a result of having to make the revisions related to this error, we made other immaterial revisions to our 2022 unaudited interim consolidated financial statements. All of the revisions have been reflected throughout this Form 10-Q.

#### Tale of Contents

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $1,057 | $1,175 | (10)% | $2,314 | $2,401 | (4)% |
| Costs, expenses and other: |  |  |  |  |  |  |
| Cost of sales | 434 | 484 | (10)% | 928 | 993 | (7)% |
| % of revenue | 41% | 41% | —% | 40% | 41% | (1)% |
| Research and development | 81 | 82 | (1)% | 162 | 163 | (1)% |
| % of revenue | 8% | 7% | 1% | 7% | 7% | —% |
| Marketing, selling and administrative | 353 | 343 | 3% | 680 | 666 | 2% |
| % of revenue | 33% | 29% | 4% | 29% | 28% | 1% |
| Amortization of intangible assets | 136 | 133 | 2% | 270 | 270 | —% |
| % of revenue | 13% | 11% | 2% | 12% | 11% | 1% |
| Asset impairment, restructuring and other special charges | 35 | 86 | (59)% | 75 | 126 | (40)% |
| Interest expense, net of capitalized interest | 74 | 67 | 10% | 138 | 119 | 16% |
| Other expense (income), net | 23 | (6) | NM | 32 | 3 | NM |
| (Loss) income before income taxes | (79) | (14) | 464% | 29 | 61 | 52% |
| % of revenue | (7)% | (1)% | (6)% | 1% | 3% | (2)% |
| Income tax expense (benefit) | 18 | (4) | NM | 23 | 20 | NM |
| Net (loss) income | $(97) | $(10) | 870% | $6 | $41 | 85% |

Certain amounts and percentages may reflect rounding adjustments.

NM - Not meaningful

### Revenue

As a global company, our products are sold in more than 90 countries, and as a result, significant portions of our revenue and expenses are recorded in currencies other than the U.S. dollar. As a result, our revenue is influenced by changes in foreign exchange rates. During the six months ended June 30, 2023 and 2022, approximately 54% and 52%, respectively, of our revenue was denominated in foreign currencies. Currency movements decreased revenue by 1% and 2% for the three and six months ended June 30, 2023, respectively, compared to the same periods in 2022.

Further, increases or decreases in inventory levels in our distribution channels can positively or negatively impact our quarterly revenue results, leading to variations in revenue. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control.

On a global basis, our revenue by product category for the three and six months ended June 30, 2023 and 2022 is summarized as follows:

*(Dollars in millions)*

|  | Three Months Ended June 30, Revenue 2023 | 2022 | % of Total Revenue 2023 | 2022 | Increase (Decrease) $ Change | % Change | CC (1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Pet Health | $518 | $610 | 49% | 52% | $(92) | (15)% | (14)% |
| Farm Animal | 527 | 553 | 50% | 47% | (26) | (5)% | (3)% |
| Subtotal | 1,045 | 1,163 | 99% | 99% | (118) | (10)% | (9)% |
| Contract Manufacturing (2) | 12 | 12 | 1% | 1% | — | —% | 1% |
| Total | $1,057 | $1,175 | 100% | 100% | (118) | (10)% | (9)% |

#### 2023 Q2 Form 10-Q \| 22

#### Tale of Contents

*(Dollars in millions)*

|  | Six Months Ended June 30, Revenue 2023 | 2022 | % of Total Revenue 2023 | 2022 | Increase (Decrease) $ Change | % Change | CC (1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Pet Health | $1,193 | $1,250 | 52% | 52% | $(57) | (5)% | (3)% |
| Farm Animal | 1,100 | 1,122 | 48% | 47% | (22) | (2)% | 1% |
| Subtotal | 2,293 | 2,372 | 99% | 99% | (79) | (3)% | (1)% |
| Contract Manufacturing (2) | 21 | 29 | 1% | 1% | (8) | (28)% | (23)% |
| Total | $2,314 | $2,401 | 100% | 100% | (87) | (4)% | (1)% |

Note: Numbers may not add due to rounding

(1) Constant Currency (CC), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange rates. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.

(2) Represents revenue from arrangements in which we manufacture products on behalf of a third party.

The effects of price, foreign exchange rates and volume on changes in revenue for the three and six months ended June 30, 2023 were as follows:

| Three months ended June 30, 2023 (Dollars in millions) | Revenue | Price | FX Rate | Volume | Total | CC |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pet Health | $518 | 4% | (1)% | (19)% | (15)% | (14)% |
| Farm Animal | 527 | 3% | (2)% | (6)% | (5)% | (3)% |
| Subtotal | 1,045 | 4% | (1)% | (12)% | (10)% | (9)% |
| Contract Manufacturing | 12 | —% | —% | 1% | —% | 1% |
| Total | $1,057 | 4% | (1)% | (12)% | (10)% | (9)% |

| Six months ended June 30, 2023 (Dollars in millions) | Revenue | Price | FX Rate | Volume | Total | CC |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pet Health | $1,193 | 5% | (2)% | (7)% | (5)% | (3)% |
| Farm Animal | 1,100 | 4% | (3)% | (3)% | (2)% | 1% |
| Subtotal | 2,293 | 4% | (2)% | (5)% | (3)% | (1)% |
| Contract Manufacturing | 21 | —% | (4)% | (23)% | (28)% | (23)% |
| Total | $2,314 | 4% | (2)% | (5)% | (4)% | (1)% |

Note: Numbers may not add due to rounding

Pet Health revenue decreased $92 million, or 15%, for the three months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and to a lesser extent, by an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the three months ended June 30, 2023, lower volumes principally related to the impact of the ERP system integration commercial blackout periods, which we believe resulted in modifications of certain customers' purchasing habits of legacy Bayer Animal Health products, shifting an estimated $65 million to $80 million in revenue from the second quarter of 2023 to the first quarter of 2023. Additionally, sales volumes were negatively impacted by declines in demand for retail parasiticide products in Spain and continued competitive pressure on certain parasiticide products in the U.S., partially offset by higher demand for pain and OTC products in the U.S. and revenue from new products.

Pet Health revenue decreased $57 million, or 5%, for the six months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and to a lesser extent, by an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the six months ended June 30, 2023, lower volumes were attributable to pressured market demand for retail parasiticide products in several international markets, competitive pressure on certain U.S. prescription products and the impact of supply disruption in vaccines in the U.S. These reductions in sales volumes were partially offset by higher demand for pain and OTC products in the U.S. and increased revenue from new products.

Farm Animal revenue decreased by $26 million, or 5%, for the three months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the three months ended June 30, 2023, lower volumes principally related to the impact of the ERP system integration commercial blackout periods, which we believe resulted in modifications of certain customers' purchasing habits of legacy Bayer Animal Health products, shifting an estimated $25 million to $30 million in revenue from the second quarter of 2023 to the first quarter of 2023. Additional revenue from new products, led by *Experior*, strength in European poultry and increased aqua demand were mostly offset by supply constraints for cattle vaccines in the U.S. and a weaker sheep season.

Farm Animal revenue decreased $22 million, or 2%, for the six months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the six months ended June 30, 2023, lower volumes were attributable to supply disruptions in U.S. cattle vaccines, reduced sales of cattle implants due to U.S. regulatory changes and generic competition. These reductions in volumes were partially offset by increased poultry demand outside of the U.S. and for aqua, and increased revenue from new products, led by *Experior.*

### Cost of Sales

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of sales | $434 | $484 | (10)% | $928 | $993 | (7)% |
| % of revenue | 41% | 41% |  | 40% | 41% |  |

Cost of sales decreased $50 million for the three months ended June 30, 2023, primarily due to lower revenue compared to the same period in the prior year, while cost of sales as a percentage of revenue was flat year over year. Product price increases and the impact of foreign exchange rates on international inventories sold were largely offset by inflationary impacts on input costs and conversion costs, lower manufacturing productivity and the impact of certain customers' elevated purchasing of legacy Bayer Animal Health products in the first quarter of 2023, ahead of our ERP system integration, as this latter event had a larger impact on our Pet Health products, which typically have higher gross margins.

Cost of sales decreased $65 million for the six months ended June 30, 2023, primarily due to lower revenue compared to the same period in the prior year. Cost of sales as a percentage of revenue decreased from 41% for the six months ended June 30, 2022 to 40% for the six months ended June 30, 2023, due to a combination of product price increases and the impact of foreign exchange rates on international inventories sold, partially offset by inflationary impacts on input costs and conversion costs and lower manufacturing productivity.

### Research and Development

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $81 | $82 | (1)% | $162 | $163 | (1)% |
| % of revenue | 8% | 7% |  | 7% | 7% |  |

Research and development expenses were essentially flat for the three and six months ended June 30, 2023, as compared to the same periods in the prior year.

### Marketing, Selling and Administrative

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Marketing, selling and administrative | $353 | $343 | 3% | $680 | $666 | 2% |
| % of revenue | 33% | 29% |  | 29% | 28% |  |

Marketing, selling and administrative expenses increased $10 million and $14 million for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, primarily driven by increases in marketing spend, employee compensation costs, travel and meeting expenses and consulting services.

### Amortization of Intangible Assets

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Amortization of intangible assets | $136 | $133 | 2% | $270 | $270 | —% |

Amortization of intangible assets was essentially flat for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, as the addition of amortization of intangible assets recorded from the acquisition of certain assets of NutriQuest during the current year was mostly offset by the impact of foreign exchange rates.

### Asset Impairment, Restructuring and Other Special Charges

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Asset impairment, restructuring and other special charges | $35 | $86 | (59)% | $75 | $126 | (40)% |

For additional information regarding our asset impairment, restructuring and other special charges, see Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements. The decrease of $51 million for both the three and six months ended June 30, 2023, compared to the prior year, was primarily due to the $59 million charge related to the expensing of an IPR&D asset licensed from BexCaFe during the three months ended June 30, 2022, which did not recur in the current year. Amounts recorded during the three and six months ended June 30, 2023 primarily represented costs associated with the implementation of new systems, programs and processes resulting from the integration of Bayer Animal Health.

### Interest Expense, Net of Capitalized Interest

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense, net of capitalized interest | $74 | $67 | 10% | $138 | $119 | 16% |

Interest expense, net of capitalized interest increased $7 million and $19 million for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, primarily due to higher interest rates on our outstanding variable-rate debt and rate increases on our Senior Notes driven by credit downgrades. The increases were partially offset by a $17 million debt extinguishment charge recorded during the three months ended June 30, 2022, which did not recur in the current year.

### Other expense (income), net

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Other expense (income), net | $23 | $(6) | NM | $32 | $3 | NM |

Other expense (income), net for the three months ended June 30, 2023, primarily consisted of a settlement provision of $15 million recorded in June related to the *Seresto* class action lawsuits (see Note 12. Commitments and Contingencies for further information). Devaluation losses of approximately $7 million related to the hyperinflationary environment in Turkey and Argentina were also recorded within other expense (income), net during the three months ended June 30, 2023 ($9 million for the six months ended June 30, 2023). Other expense (income), net for the six months ended June 30, 2023, also included foreign exchange losses and mark-to-market adjustments on equity investments.

### Income tax expense (benefit)

*(Dollars in millions)*

|  | Three Months Ended June 30, 2023 | 2022 | % Change | Six Months Ended June 30, 2023 | 2022 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Income tax expense (benefit) | $18 | $(4) | NM | $23 | $20 | NM |
| Effective tax rate | (23.0)% | 28.6% |  | 79.9% | 32.3% |  |

Income tax expense increased to $18 million for the three months ended June 30, 2023, compared to an income tax benefit of $4 million in the same period of the prior year. The effective tax rate was negative for the three months ended June 30, 2023, and differed from the statutory income tax rate primarily due to the earnings mix of income in jurisdictions with statutory tax rates higher than the U.S. and losses in the U.S. and various foreign affiliates for which there was no tax benefit, as valuation allowances have been established in those jurisdictions. The income tax benefit for the three months ended June 30, 2022, was primarily attributable to a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the three months ended June 30, 2022.

Income tax expense increased $3 million for the six months ended June 30, 2023, compared to the same period in the prior year, and the effective tax rate increased to 79.9%, compared to 32.3% in the prior year period. These increases were primarily due to changes in the earnings mix between periods resulting in projected losses in the U.S. and various other foreign affiliates for which there was no tax benefit, as valuation allowances had been established in those jurisdictions. Income tax expense for the six months ended June 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the three months ended June 30, 2022.

### Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our business evolves, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.

We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations, such as principal and interest payments, as well as interest rate swaps, operating lease payments, purchase obligations and costs associated with business integrations. As of June 30, 2023, we had cash and cash equivalents of $367 million and unused borrowing capacity on our Revolving Credit Facility of approximately $500 million. In addition, we have the ability to access capital markets to obtain debt financing for longer-term funding, if required. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.

Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As market conditions change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our 2022 Form 10-K.

### Cash Flows

The following table provides a summary of cash flows from operating, investing and financing activities for the six months ended June 30, 2023 and 2022:

*(Dollars in millions)*

| Net cash (used for) provided by: | Six Months Ended June 30, 2023 | 2022 | $ Change |
| --- | ---: | ---: | ---: |
| Operating activities | $(84) | $250 | $(334) |
| Investing activities | (98) | (66) | (32) |
| Financing activities | 213 | (296) | 509 |
| Effect of exchange-rate changes on cash and cash equivalents | (9) | (19) | 10 |
| Net increase (decrease) in cash and cash equivalents | $22 | $(131) | $153 |

#### Operating activities

Cash used for (provided by) operating activities decreased $334 million to a use of cash of $84 million for the six months ended June 30, 2023, compared to cash provided by operating activities of $250 million for the six months ended June 30, 2022. The decrease in cash from operating activities primarily relates to changes in operating assets and liabilities, particularly accounts receivable and inventories, as well as $132 million of proceeds from interest rate swap settlements that were received during the six months ended June 30, 2022, that did not recur in the current year.

In the past, we have extended our payment terms for distributors on occasion. Specifically, due to the ERP system integration completed in the second quarter of 2023, we increased inventories on hand and extended payment terms on sales totaling $35 million for some customers during the first quarter of 2023 to ensure that our product was available for a period of time during which there were no shipments. Although we presently have no plans to do so in the future, it is possible that we will need to extend payment terms in certain situations, for example, as a result of competitive pressures, macroeconomic factors and the need for certain inventory levels in our distribution channels to avoid supply disruptions. In the event we do extend payment terms in the future, such extensions could result in additional uses of cash.

#### Investing activities

Cash used for investing activities was $98 million for the six months ended June 30, 2023 as compared to $66 million for the six months ended June 30, 2022. The increase in cash used for investing activities was primarily driven by cash paid for the acquisition of certain assets of NutriQuest of $16 million during the six months ended June 30, 2023 as well as a year over year increase in cash paid for intangible assets, primarily related to development/regulatory milestones achieved upon FDA approval of the original new animal drug application for *Bexacat* in December 2022 (see Note 4. Acquisitions, Divestitures and Other Arrangements for further information).

#### Financing activities

Cash provided by financing activities was $213 million for the six months ended June 30, 2023 as compared to cash used for financing activities of $296 million for the six months ended June 30, 2022. Cash provided by financing activities during the six months ended June 30, 2023, reflected proceeds of $250 million from our revolving credit facility, partially offset by the repayment of indebtedness outstanding under our long-term borrowings. Cash used for financing activities of $296 million during the six months ended June 30, 2022, primarily reflected the tender offer completed during the period as well as net repayments on our revolving credit facility and the repayment of indebtedness outstanding under our term loan B credit facility, partially offset by proceeds from the issuance of our incremental term facilities.

### Description of Indebtedness

For a complete description of our existing debt and available credit facilities as of June 30, 2023 and December 31, 2022, see Note 10. Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2022 Form 10-K. New developments are discussed in Note 8. Debt of this Form 10-Q.

### Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2022 Form 10-K. There were no significant changes or developments in the application of our critical accounting policies during the six months ended June 30, 2023.

#### Goodwill Impairment Testing

We evaluate goodwill for impairment on an annual basis and when certain qualitative impairment indicators are present that would more likely than not reduce the fair value of our single reporting unit below its carrying amount.

In the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a goodwill impairment review. Based on our qualitative assessment, we concluded that it was more likely than not that the fair value of our single reporting unit was less than its carrying value, and therefore, we were required to perform a quantitative goodwill impairment test, which involved comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimated the fair value of our single reporting unit using a combination of the income and market approach.

Significant management judgment is required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that are used in the discounted cash flow method of valuation. These include, but are not limited to, estimates and assumptions regarding (1) our future cash flows, revenue, and other profitability measures, (2) the long-term growth rate of our business, and (3) the determination of our weighted-average cost of capital, which is a factor in determining the discount rate. We make these judgments based on our historical experience, relevant market size, historical pricing of similar products and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, results of research and development and changes in macroeconomic conditions, including rising interest rates and inflation. A change in these assumptions or the use of alternative estimates and assumptions could have a significant impact on the estimated fair value and may expose us to goodwill impairment losses.

As a result of our quantitative assessment, we estimated that the fair value of our single reporting unit exceeded the carrying amount by more than 20% as of September 30, 2022 and, therefore, no impairment existed with respect to our goodwill. Given our market capitalization remained lower than our book value as of June 30, 2023, we reevaluated our impairment testing from a qualitative perspective as of this date, with no change to our previous conclusion that no impairment exists.

## Market risk

As filed, 2,911 characters.

### Foreign Exchange Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.

We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. We have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, beginning in the second quarter of 2018, the functional currency of our Argentina subsidiary changed from the local currency to the U.S. dollar. During the six months ended June 30, 2023, revenue in Argentina represented less than 1% of our consolidated revenue. Assets held in Argentina as of June 30, 2023 represented less than 1% of our consolidated assets.

During the first quarter of 2022, Turkey’s three-year cumulative inflation rate also exceeded 100%, and as such, we concluded that Turkey became a hyperinflationary economy for accounting purposes. As of April 1, 2022, we applied hyperinflationary accounting for our subsidiary in Turkey and changed its functional currency from the Turkish lira to the U.S. dollar. During the six months ended June 30, 2023, revenue in Turkey represented less than 1% of our consolidated revenue. Assets held in Turkey as of June 30, 2023 represented less than 1% of our consolidated assets.

The application of hyperinflationary accounting for our subsidiaries in Argentina and Turkey have resulted in approximately $9 million of foreign currency related expense during the six months ended June 30, 2023, which was included within other expense (income), net. In the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.

### Interest Risk

During the first quarter of 2023, our variable-rate debt was subject to fluctuations in interest rates based on both LIBOR and Term SOFR. Effective April 1, 2023, we transitioned the reference rate used in our credit facilities, and as a result, our variable-rate debt is now exclusively indexed to Term SOFR, including the new Securitization Facility entered into on August 3, 2023 (see Note 8. Debt for further details). As of June 30, 2023, we held interest rate swap agreements with a notional value of $3,800 million that had the economic effect of modifying this amount of our variable-rate debt to fixed-rate. Subsequent to the issuance of the Securitization Facility and early redemption of the 4.272% Senior Notes due 2023, approximately 75% of our long-term indebtedness now bears interest at a fixed-rate (including variable-rate converted to fixed-rate through the use of interest rate swaps).

## Controls and procedures

As filed, 1,946 characters.

(a) *Evaluation of Disclosure Controls and Procedures*. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized and reported on a timely basis.

Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of June 30, 2023. As disclosed in Item 9A of Part II of our 2022 Form 10-K, management concluded that a material weakness existed as of December 31, 2022 resulting from the ineffective review of the annual income tax provision, including the valuation allowance related to deferred tax assets. We have developed a remediation plan which requires the effective operation of certain quarterly and annual controls. Therefore, the material weakness cannot be fully remediated until we assess the effectiveness of our internal control over financial reporting for the year ending December 31, 2023. Based on this evaluation, the chief executive officer and the chief financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures remained ineffective.

(b) *Changes in Internal Controls*. During the second quarter of 2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than the aforementioned material weakness.

## Risk factors

As filed, 5,455 characters.

Our risk factors are documented in Item 1A of Part I of our 2022 Form 10-K, which is incorporated herein by reference. Other than the revisions set forth below, there have been no material changes from the risk factors previously disclosed in the 2022 Form 10-K.

The following risk factors have been changed from the risk factors that were previously disclosed:

***Unanticipated safety, quality or efficacy concerns or identified concerns associated with our products may harm our reputation and have an adverse impact on our performance.***

Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, potentially leading to product recalls, withdrawals or suspended or reduced sales, as well as product liability and other claims. Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales.

For example, lawsuits seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been filed against us arising out of the use of *Seresto*, a non-prescription flea and tick collar for cats and dogs, based on media reports alleging that the collar has caused injury and death to pets. Further, in 2021, the U.S. House of Representatives' then-subcommittee chair requested that we produce certain documents and information related to the *Seresto* collar, made a request to temporarily remove *Seresto* collars from the market and, during a hearing at which our President and Chief Executive Officer (CEO) testified, again called for removal of the collars from the market.

Since that time, on July 13, 2023, the EPA announced the completion of its comprehensive, multi-year review of the *Seresto* flea and tick collar and confirmed the continued registration of the collar. However, if any similar claims with respect to our other products are resolved adversely to us, or if a regulatory agency determines that a recall or cancellation of registrations of any of our products is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.

In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products in general, by food producers, veterinarians and pet owners. Any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns, including those relating to *Seresto*, and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.

***Changes in our credit rating could increase our interest expense and restrict our access to, and negatively impact the terms of, current or future financings or trade credit.***

Credit rating agencies continually revise their ratings for the companies that they follow, including us. Credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. We cannot be sure that credit rating agencies will maintain their ratings on us and certain of our debt. The acquisition of Bayer Animal Health had a negative impact on our credit ratings, leading to higher borrowing expenses. Additionally, S&P, Moody's and Fitch downgraded our credit ratings in February, March and April 2023, respectively. Because the ratings of certain of our senior unsecured notes have been downgraded, we are required to pay additional interest under the senior unsecured notes. Any further downgrades could result in requirements to pay additional interest under the senior unsecured notes. Moreover, any decision to downgrade our ratings could restrict our access to, and negatively impact the terms of, current or future financings and trade credit extended by our suppliers of raw materials or other vendors.

### Changes in interest rates may adversely affect our earnings and/or cash flows.

During the first quarter of 2023, certain of our credit facilities bore interest at variable interest rates that used the London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we transitioned the reference rate used in our credit facilities from LIBOR to Term SOFR.

Term SOFR measures the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. While this change did not have a material impact on our condensed consolidated financial statements, we continue to be exposed to the risk of rising interest rates, given our level of variable-rate indebtedness. Term SOFR rate increases over the course of 2023 have led to an increase in both our interest expense and cash paid for interest, and any further increases in Term SOFR rates would expose us to additional interest rate risk and additional expense. Further, we are exposed to the risk of rising interest rates to the extent we fund our operations with short-term or variable-rate borrowings.

Filed Aug 7, 2023.
Source: SEC EDGAR, the filing index for accession 0001739104-23-000013. Last ingested by Listed: Nov 13, 2026, 16:18 ET. No prices; not investment advice.
